Funder
Prostate Cancer Foundation
Publisher
Springer Science and Business Media LLC
Reference9 articles.
1. Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R, et al. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N. Engl J Med. 2020;382:2187–96.
2. Lopes RD, Higano CS, Slovin SF, Nelson AJ, Bigelow R, Sørensen PS, et al. Cardiovascular safety of degarelix versus leuprolide in patients with prostate cancer: the primary results of the PRONOUNCE randomized trial. Circulation. 2021;144:1295–307.
3. Pinthus JH, Duivenvoorden WCM. Cardiovascular risk in ADT recipients: does the type of ADT matter? Prostate Cancer Prostatic Dis. 2024.
4. Duivenvoorden WCM, Margel D, Subramony Gayathri V, Duceppe E, Yousef S, Naeim M, et al. Follicle-Stimulating Hormone Exacerbates Cardiovascular Disease in the Presence of Low or Castrate Testosterone Levels. JACC Basic Transl Sci. 2024;9:364–79.
5. Hahn AW, Thoman W, Koutroumpakis E, Abdulla A, Subudhi SK, Aparicio A, et al. Cardiometabolic healthcare for men with prostate cancer: an MD Anderson Cancer Center experience. Cardiooncology. 2023;9:33.